Collegium Pharmaceutical (COLL) Current Deferred Revenue (2014 - 2026)

Collegium Pharmaceutical's Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $667000.0 for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 99.51% year-over-year to $667000.0; the TTM figure through Mar 2026 stood at $667000.0 (down 99.51% YoY), while the FY2025 annual figure was $667000.0, down 98.27% from the prior year.
• Current Deferred Revenue was $667000.0 for Q1 2026 at Collegium Pharmaceutical, roughly flat from $667000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $149.8 million in Q4 2023 to a low of $667000.0 in Q3 2025.
• Historically, Current Deferred Revenue has averaged $60.9 million across 5 years, with a median of $33.7 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Deferred Revenue surged 579.24% in 2023, then sank 99.51% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $22.1 million in 2022, then soared by 579.24% to $149.8 million in 2023, then tumbled by 74.3% to $38.5 million in 2024, then tumbled by 98.27% to $667000.0 in 2025, then changed by 0.0% to $667000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $667000.0 (Q1 2026), $667000.0 (Q4 2025), and $667000.0 (Q3 2025), per Business Quant data.